Home > Boards > US OTC > Miscellaneous > American BriVision Holding Corp. (ABVC)

Name change filed with the NVSOS ->

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DaReal Member Profile
Member Level 
Followed By 123
Posts 3,010
Boards Moderated 0
Alias Born 02/21/10
160x600 placeholder
DaReal Member Level  Friday, 01/08/16 05:29:35 PM
Re: None
Post # of 29 
Name change filed with the NVSOS ->


A/S increased to 350M

Company Age: 6 Months

Facebook Acc created 30th Dec'15

BioLite, Inc. formed an alliance with American BriVision Corporation (ABVC) to co-develop the US market for its new drugs

including combination therapy for Triple-negative breast cancer (TNBC), cancer combination therapy,

Hematology-Chronic Lymphocytic Leukemia (HCLL), Attention Deficit Hyperactivity Disorder(ADHD) and Major Depressive Disorder.

For the cancer combination therapy project, BioLite, Inc. has initiated the co-operation with an oversea partner, and is also technically

supported by a US renowned cancer center. These partners also came to support the BioLite-sponsored

International Symposium on Hematology & Oncology held in Oct., 2015, Taipei.


NASDAQ 2018... ->

(Central News Agency reporters Luo Xiuwen Taipei October 1, 2015 e) The special Bio Board of Directors recently passed a major resolution, an alliance of US companies American BriVision Corporation (Code ABVC) to jointly develop the North American pharmaceutical market, the Department can obtain special authorization gold, milestone revenue and premium share.

US ABVC cooperation with international leading medical and research center for cancer, focusing on the blood-tumor drugs, central nervous system drugs and market development of high-end medical equipment, conduct clinical trials translational research industry, sublicense large international pharmaceutical companies, to open up global markets.

ABVC end of this year the system in the US OTC (Over-The-Counter Market) listing, and planning for 2018 in the US NASDAQ (NASDAQ) listed on the board.

The special Biotechnology (6458) focus on high-end medical materials, magnetic nano new formulations of new drugs, protein drugs, transdermal attract technology to develop new forms of patented layout of the world's major countries, has been jointly reviewed by the Ministry of Economic Affairs and the Ministry of Health, Welfare, with " high-end medical material "and" drug development "Pom new drugs Emerging biotech companies. The Board has invested 700 million yuan by the construction of the output value of billions of PIC / SGMP high-end medical material plant.

via translate: https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=http%3A%2F%2Fmoney.yam.com%2Fnews%2Fcnabc%2Ffn_news%2F201510%2F20151001306230.html

and another chinese News Hit:

Wright, to join the United States Department of Special ABVC grab new drug markets in North America

Wright Medical Group's Health Department of Special biotechnology (6458-TW) and Wright Biomedical alliance ABVC US companies (American BriVision Corporation), to jointly develop the North American market for triple-negative breast cancer, solid tumors Anti-PD1, chronic lymphocytic leukemia, severe depression therapy clinical trials with attention deficit hyperactivity disorder psychosis 5, and insulin transdermal system of import and sales rights market.

Wright said another international market attention, "chronic lymphocytic leukemia combination therapy" with Japan strategic alliance partners to develop from the start of clinical Phase II and get top-ranked American Cancer tumor medical research institutions technical support.

Wright pointed out that cancer tumors has sent four world-class research institutions and scholars with a number of researchers, support 2015 International Symposium exclusive association with blood tumor diseases, respectively Speaker efficacy of herbal maitake extract anticancer aspects, MBG in the hematopoietic system and the effect on the immune system, natural medicine and hematologic malignancies overview, botanical extracts used in combination in the treatment of chronic lymphocytic leukemia. Bring the world's latest medical information and advanced treatment methods for Taiwan's blood cancer specialist.

Wright pointed out closer, "chronic lymphocytic leukemia plant new drug combination therapy," Taiwan's innovative technology is based on a starting point, combined with maitake extract plant factories Japan strategic partnership, cooperation and America's top cancer tumor clinical trials of medical research institutes, three strong contribution to the effort to work together all health development goals, to build Taiwan's biotech industry and international health research linking innovation model.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist